Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function

European Journal of Clinical Pharmacology

Volumn 54, Issue 4, 1998, Pages 341-345

  Hoogkamer, J F W ^a   Kleinbloesem, C H ^a   Ouwerkerk, M ^a   Hogemann A ^b   Nokhodian, A ^c   Kirch, W ^c   Weidekamm, E ^a  

^a Clin Pharma Research AG   (Switzerland)

^b Takeda Pharma GmbH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Candesartan; Hepatic impairment

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGED; BENZIMIDAZOLES; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0031847699     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050471     Document Type: Article

References (10)

1. Timmermanns PB, Wong P, Chiu A, Herblin W, Benfield P, Carini D, Lee R, Wexler R, Saye JA, Smith R (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251
2. Israili ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of literature and pathophysiology. Ann Intern Med 117: 234-242
3. Delacrétraz E, Nussberger J, Biollaz J, Waeber B, Brunner HR (1995) Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25: 14-21
4. Heuer HJ, Schöndorfer G, Högemann AM (1997) Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 11 [Suppl. 2]: S55-S56
5. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 11 [Suppl. 2]: S27-S28
6. Dylewicz P, Kirch W, Santos SR, Hutt HJ, Mönig H, Ohnhaus EE (1987) Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 32: 563-568
7. Miyabayashi T, Okuda T, Motohashi M, Izawa K, Yashiki T (1996) Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine. J Chromatogr Biomed Sci Appl 677: 123-132
8. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
9. Riddell JG (1997) Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil. J Hum Hypertens 11 [Suppl. 2]: S29-S30
10. Hübner R, Högemann AM, Sunzel M, Riddell JG (1997) Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11 [Suppl. 2]: S19-S25